2026 ICD-10-CM Diagnosis Code T48.295SAdverse effect of other drugs acting on muscles, sequela

ICD-10-CM Codes›S00–T88›T36-T50›T48

ICD-10-CM T48.295S
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

T48.295S is a billable ICD-10-CM diagnosis code for adverse effect of other drugs acting on muscles, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. Coders also document this condition as orciprenaline adverse reaction. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Poisoning/toxic effect/adverse effects/underdosing, sequela.

Code Identity

ICD-10-CM Code
T48.295S
Billable Status
Yes — Valid for Submission
Code Describes
Adverse effect of other drugs acting on muscles, sequela
Short Description
Adverse effect of other drugs acting on muscles, sequela
Same as the full description in the CMS dataset.
Parent Code
T48.295
Adverse effect of other drugs acting on muscles

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT36-T50Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
CategoryT48Poisoning by, adverse effect of and underdosing of agents primarily acting on smooth and skeletal muscles and the respiratory system
This CodeT48.295SAdverse effect of other drugs acting on muscles, sequela

Code EditsBilling

Medicare Code Editor checks that affect claim validity for T48.295S.

Unacceptable principal diagnosis
There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Present on Admission (POA)Billing

T48.295S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Orciprenaline adverse reaction

Coding GuidelinesGuidance

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of agents primarily acting on smooth and skeletal muscles and the respiratory system (T48). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR INJ075
Poisoning/toxic effect/adverse effects/underdosing, sequela
Default principal diagnosis: inpatient No · outpatient Yes

Clinical InformationClinical

  • Metaproterenol

    a beta-2 adrenergic agonist used in the treatment of asthma and bronchial spasm.

Table of Drugs and ChemicalsClinical

Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.

SubstanceAccidentalSelf-harmAssaultUndeter­minedAdverse
Effect		Under­dosing
BotoxT48.291T48.292T48.293T48.294T48.295T48.296
BruceineT48.291T48.292T48.293T48.294T48.295T48.296
DipropylineT48.291T48.292T48.293T48.294T48.295T48.296
HydrastineT48.291T48.292T48.293T48.294T48.295T48.296
LututrinT48.291T48.292T48.293T48.294T48.295T48.296
MetaproterenolT48.291T48.292T48.293T48.294T48.295T48.296
OrciprenalineT48.291T48.292T48.293T48.294T48.295T48.296

Patient EducationClinical

Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

The full article covers:

  • What is a drug interaction?
  • What are side effects?
  • What are drug allergies?
  • How can I stay safe when taking medicines?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert T48.295S to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
909.5 Lte efct advrs efct drug
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.
ICD-9-CM
E945.3 Adv eff musc agt NEC/NOS
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About T48.295SOverview

Is T48.295S (Adverse effect of other drugs acting on muscles) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of other drugs acting on muscles, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What does the 7th character S in T48.295S mean?

The final character S makes this a sequela code: it reports a lingering problem that remains after the adverse effect of other drugs acting on muscles itself has resolved, not the original event.

What MS-DRG does T48.295S group to?

On inpatient claims, adverse effect of other drugs acting on muscles, sequela maps to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.

Can T48.295S be a principal diagnosis?

No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of other drugs acting on muscles, sequela describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.

Is T48.295S exempt from POA reporting?

Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for adverse effect of other drugs acting on muscles, sequela on inpatient claims.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.